NCT05177211

Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

A Phase 2 Study of Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the effectiveness, safety, and tolerability of a study drug called fedratinib in participants with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) and chronic neutrophilic leukemia (CNL).

Conditions

• Myeloproliferative Neoplasm
• Chronic Neutrophilic Leukemia
• MDS

Interventions

Type	Name	Description
DRUG	Fedratinib Pill	Participants will be given Fedratinib at a dose of 400 mg PO once daily (4-100 mg capsules). Fedratinib can be given at any time during the day, but patients are advised to take the dose at the same approximate time every day.

Timeline

• Start date: 2022-03-01
• Primary completion: 2025-04-10
• Completion: 2026-04-01
• First posted: 2022-01-04
• Last updated: 2026-04-17
• Results posted: 2026-04-17

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study